Home / Articles / Growing Teratoma Syndrome

Growing Teratoma Syndrome

Growing Teratoma Syndrome: When Chemotherapy Makes a Tumor Grow Bigger

Introduction

In the world of oncology, there are few scenarios more paradoxical — or more alarming — than watching a mass grow larger while a patient is actively receiving chemotherapy. For men with advanced non-seminomatous germ cell tumors (NSGCTs) of the testis, this phenomenon has a name: Growing Teratoma Syndrome (GTS). It is not treatment failure. It is not cancer progressing through chemotherapy. It is something stranger and, once understood, entirely manageable — but only if the clinical team recognizes it.

Growing Teratoma Syndrome occurs when mature teratoma elements within a metastatic NSGCT expand rapidly during or after platinum-based chemotherapy, even as serum tumor markers normalize. Because teratoma is biologically distinct — chemoresistant, yet not malignant in the classical sense — it follows its own rules. Understanding those rules can mean the difference between unnecessary panic and precisely timed surgery that cures the patient.

What Is Teratoma, and Why Does It Behave Differently?

Teratoma Within the NSGCT Spectrum

Non-seminomatous germ cell tumors are a histologically diverse group, typically containing mixtures of:

  • Embryonal carcinoma — high-grade, aggressive
  • Yolk sac tumor — AFP-producing
  • Choriocarcinoma — β-hCG-producing, highly vascular
  • Mature teratoma — differentiated tissue resembling normal body structures (cartilage, glandular epithelium, neural tissue, bone)
  • Immature teratoma — embryonic-type tissue, intermediate behavior

Teratoma is unique among these components because it is histologically benign — its cells are differentiated and do not invade or metastasize in the traditional sense. Yet it is also chemoresistant: the same platinum-based drugs that eradicate embryonal carcinoma and yolk sac tumor have essentially no effect on mature teratoma cells.

The Chemotherapy Paradox

When a patient with mixed NSGCT metastases receives BEP chemotherapy (bleomycin, etoposide, cisplatin):

  • Malignant components (embryonal carcinoma, choriocarcinoma) are killed → tumor markers fall → masses shrink
  • Teratoma component remains viable → it is no longer suppressed by the surrounding malignant cells → it begins to expand, sometimes rapidly

This selective survival and subsequent expansion is the biological engine of Growing Teratoma Syndrome. The mass grows — sometimes dramatically — while AFP and β-hCG normalize, creating a deeply counterintuitive clinical picture.

Defining Growing Teratoma Syndrome

Diagnostic Criteria

Growing Teratoma Syndrome is defined by the simultaneous occurrence of three features:

  1. Enlarging retroperitoneal (or other) mass during or after platinum-based chemotherapy
  2. Normalizing or normal serum tumor markers (AFP, β-hCG, LDH)
  3. Pathological confirmation of mature teratoma in the resected specimen — no viable malignant GCT

All three criteria must be present. An enlarging mass with rising markers represents chemotherapy-refractory viable GCT, not GTS — an entirely different and more serious situation.

How Common Is It?

GTS is uncommon but not rare within the testicular cancer population:

  • Estimated incidence of approximately 2–7% of all patients with metastatic NSGCT undergoing chemotherapy
  • More common in patients with large-volume retroperitoneal metastases at diagnosis
  • More frequent when the primary tumor contains significant teratoma elements
  • Can occur during chemotherapy or in the months following its completion

Clinical Presentation and Locations of GTS

Where Does It Occur?

While the retroperitoneum is the most common site — reflecting the primary lymphatic drainage of the testis — GTS can arise wherever NSGCT has metastasized:

Location Approximate Frequency Key Clinical Features
Retroperitoneum ~70–80% Mass effect on bowel, ureters, vessels
Mediastinum ~10–15% Dyspnea, chest pain, SVC syndrome
Lung ~5–10% Respiratory symptoms, pleural effusion
Neck/supraclavicular Rare Palpable mass
Liver Rare Abdominal fullness, pain
Brain Very rare Neurological symptoms

Symptoms Caused by Growing Retroperitoneal Teratoma

Expanding retroperitoneal masses cause symptoms through compression and displacement of adjacent structures:

  • Ureteral obstruction → hydronephrosis, flank pain, renal impairment
  • Bowel compression or displacement → constipation, early satiety, abdominal distension
  • Vascular encasement → lower extremity edema (venous), rarely ischemia
  • Abdominal or back pain from mass effect
  • Palpable abdominal mass in advanced cases

The paradox of a patient feeling increasingly unwell — with worsening abdominal symptoms — while their tumor markers normalize is a hallmark presentation that should immediately raise suspicion for GTS.

Diagnosis: Imaging Is Everything

CT Scanning

Contrast-enhanced CT of the chest, abdomen, and pelvis is the cornerstone of surveillance and diagnosis. GTS appears as:

  • Enlarging retroperitoneal mass with variable density — may appear heterogeneous, cystic, or contain calcifications and fat
  • No significant FDG uptake on PET — mature teratoma is metabolically inactive, distinguishing GTS from viable malignant GCT
  • Displacement or compression of adjacent structures (ureters, great vessels, bowel)

The rate of growth can be remarkable — masses doubling in size within weeks have been reported. Serial imaging during chemotherapy cycles reveals the characteristic pattern: markers falling, mass expanding.

The Role of PET/CT

As discussed in prior research on post-chemotherapy restaging of NSGCTs, PET/CT is of limited value in definitively diagnosing GTS because:

  • Mature teratoma is FDG-negative → appears “cold” on PET, potentially reassuring but misleading about size progression
  • Viable malignant GCT is FDG-positive — a hot PET lesion in a patient with normalizing markers should prompt biopsy consideration

PET’s primary role in the GTS context is to exclude viable malignant transformation, not to characterize the growing teratoma itself.

Tumor Markers

The marker profile in GTS is critical to diagnosis:

Marker Expected Finding in GTS Significance if Elevated
AFP Normal or normalizing Suggests residual yolk sac tumor — not GTS
β-hCG Normal or normalizing Suggests residual choriocarcinoma — not GTS
LDH Normal or normalizing Nonspecific but should trend down

Persistently elevated or rising markers with a growing mass = chemotherapy-refractory GCT, not GTS. This distinction is urgent and changes management entirely.

Treatment: Surgery Is the Only Cure

Why Chemotherapy Doesn’t Work

By definition, mature teratoma does not respond to platinum-based chemotherapy. Additional chemotherapy cycles in the setting of confirmed or suspected GTS are not only ineffective — they delay the only effective intervention and expose the patient to additional toxicity. The treatment of Growing Teratoma Syndrome is exclusively surgical.

Post-Chemotherapy RPLND for GTS

PC-RPLND (post-chemotherapy retroperitoneal lymph node dissection) is the definitive treatment for retroperitoneal GTS. Surgical principles include:

  1. Complete resection of all visible teratoma — incomplete resection carries high risk of local recurrence and re-growth
  2. Early intervention — deferring surgery allows further growth, increasing technical difficulty, vascular encasement, and risk of malignant transformation
  3. En bloc resection when adjacent organs are involved — nephrectomy, bowel resection, or vascular reconstruction may be required
  4. Experienced surgical team — GTS resections at large retroperitoneal masses are among the most technically demanding operations in urological oncology

Surgical complexity correlates directly with mass size. Early recognition and timely surgery — before the mass becomes massively adherent to the great vessels — dramatically improves resectability and reduces morbidity.

The Role of Laparoscopic and Robotic Approaches

For standard post-chemotherapy RPLND, including select GTS cases with moderate-volume retroperitoneal disease, laparoscopic and robotic-assisted PC-RPLND are performed at high-volume centers. These minimally invasive approaches offer:

  • Reduced blood loss and transfusion requirements
  • Shorter hospitalization
  • Faster recovery without compromising oncological completeness

However, for very large GTS masses with vascular or multi-organ involvement, open surgery via midline or thoracoabdominal incision remains standard — providing the exposure necessary for safe resection.

The Danger of Malignant Transformation

Teratoma With Malignant Transformation (TMT)

A feared but real complication of untreated or incompletely resected teratoma is somatic malignant transformation — in which a mature teratomatous component undergoes secondary malignant change, developing into a non-GCT malignancy such as:

  • Rhabdomyosarcoma
  • Adenocarcinoma
  • Primitive neuroectodermal tumor (PNET)
  • Angiosarcoma

These secondary malignancies are:

  • Chemoresistant to standard GCT regimens
  • Radioresistant in most cases
  • Treated with sarcoma or carcinoma-specific protocols with generally poor outcomes
  • Best prevented by early, complete surgical resection of teratoma before malignant transformation occurs

This underscores the urgency of recognizing and operating on GTS promptly — a growing teratoma left in place is not a stable, benign mass indefinitely. It is a transformation risk that increases with time and size.

Surveillance After Surgery

Following complete resection of GTS, long-term follow-up includes:

  • Serum tumor markers — AFP, β-hCG, LDH at regular intervals
  • CT imaging — to detect local recurrence or new sites of teratoma growth
  • Duration: minimum 5 years, with lifelong awareness given teratoma’s capacity for late recurrence
  • Recurrence after complete resection is uncommon (~5–15%) but can occur years later

Conclusion

Growing Teratoma Syndrome is one of testicular cancer’s most instructive paradoxes: a mass that grows while treatment appears to be working. The key to managing it well lies in three things — recognizing the characteristic pattern of enlarging mass with normalizing markers, resisting the temptation to add more chemotherapy, and proceeding to surgery promptly and completely.

For patients navigating this diagnosis, the reassurance is real: GTS is not cancer progressing through therapy. It is a curable complication of successful chemotherapy, treatable with expert surgery. The outcomes for men who undergo timely, complete resection are excellent, and the risk of recurrence is low.

Your next steps if GTS is suspected:

  • Ensure your care is coordinated at a center with dedicated testicular cancer and urological oncology expertise
  • Confirm tumor marker trends at every chemotherapy cycle — normalization alongside growth is the GTS signature
  • Request PET/CT to exclude viable malignant GCT before attributing growth to teratoma
  • Do not accept “wait and watch” for a confirmed growing retroperitoneal mass with normal markers
  • Ask your surgical team about their volume of post-chemotherapy RPLND cases — outcomes correlate directly with experience
  • Consider sperm banking before any additional surgery if fertility preservation has not yet been addressed